Zanzalintinib

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neoadjuvant Treatment

Conditions

Neoadjuvant Treatment, Thyroid Cancer

Trial Timeline

Jul 22, 2025 → Oct 1, 2030

NCT ID

NCT06959511

About Zanzalintinib

Zanzalintinib is a phase 2 stage product being developed by Exelixis for Neoadjuvant Treatment. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06959511. Target conditions include Neoadjuvant Treatment, Thyroid Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Neoadjuvant Treatment were approved

Approved (0) Terminated (0) Active (1)

🔄SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07218666	Phase 2	Recruiting	May 1, 2026	Dec 1, 2027	Aggressive Variant Prostate Carcinoma
NCT07428616	Phase 2	Recruiting	May 1, 2026	Sep 1, 2029	Meningioma
NCT07185945	Phase 2	Recruiting	Feb 1, 2026	Mar 1, 2029	Advanced Urothelial Carcinoma
NCT06926634	Phase 2	Recruiting	Dec 9, 2025	Dec 31, 2034	High Grade Neuroendocrine Neoplasms
NCT07193550	Phase 2	Recruiting	Dec 5, 2025	Oct 31, 2031	Bone Sarcomas
NCT06959511	Phase 2	Recruiting	Jul 22, 2025	Oct 1, 2030	Neoadjuvant Treatment
NCT06962332	Phase 1	Recruiting	May 13, 2025	Apr 1, 2026	Hepatic Impairment

Competing Products

4 competing products in Neoadjuvant Treatment

See all competitors

Product	Company	Stage	Hype Score
SHR-A1811 + Trastuzumab Emtansine	Jiangsu Hengrui Medicine	Phase 3	47
Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib	Pfizer	Phase 2	35
E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6)	Adlai Nortye	Phase 1	19
Pembrolizumab, Eftilagimod alfa	Immutep	Phase 2	29